The approval is tightly defined: the system will be for patients ineligible for surgery and with anatomy unfavorable for TEER ...

Abbott's Tendyne transcatheter mitral valve replacement (TMVR) system was approved by the FDA and indicated for those with ...

The FDA approved Abbott's Tendyne minimally invasive heart replacement for mitral valve disease that could disqualify ...

Abbott Laboratories (NYSE:ABT) recently received FDA approval for its Tendyne™ TMVR system, a significant milestone enhancing its cardiovascular product portfolio. Over the past month, Abbott's stock ...

Abbott Laboratories (NYSE:ABT) has received FDA approval today for its Tendyne™ transcatheter mitral valve replacement (TMVR) ...

ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.

Abbott (NYSE: ABT) announced today that it received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR ...

Abbott announced the FDA approved its transcatheter mitral valve replacement system for patients with severe mitral annular ...

The FDA gave the OK for the North Chicago-based medical device maker's Tendyne transcatheter mitral valve replacement.

ABBOTT PARK, Ill., Jan. 30, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its Tendyne™ Transcatheter Mitral Valve Implantation (TMVI) system received CE Mark and is now approved ...

Via Christi’s Structural Heart team was the first in the nation to participate in the U.S. pivotal trial of Abbott’s Tendyne transcatheter mitral valve replacement system in its hybrid OR ...